[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neovascular-age-related-macular-degenerationnamd\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neovascular-age-related-macular-degenerationnamd":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,60],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100640265","prospective-single-arm-observational-study-of-faricimab-in-the-treatment-of-neovascular-age-related-macular-degeneration-namd-100640265",false,"NCT07581782","Prospective, Single Arm, Observational Study of Faricimab in the Treatment of Neovascular Age-related Macular Degeneration (nAMD)","Inclusion Criteria:\n\n* Age ≥50 years, any gender.\n* The study eye must have active treatment-naïve macular neovascularization (MNV) secondary to AMD, confirmed by the investigator based on OCT images showing the presence of intraretinal fluid (IRF) or subretinal fluid (SRF) involving the fovea.\n* The study eye must have a best-corrected visual acuity (BCVA) measured using the 4-meter ETDRS chart of 24-78 ETDRS letters (approximately Snellen equivalent 20\u002F320 - 20\u002F32).\n* Central subfield thickness (CST) ≥300 μm.\n* The study eye has sufficiently clear ocular media and adequate pupillary dilation.\n* Women of childbearing potential must use contraceptive measures during the study treatment period and for at least 3 months after the last dose.\n* The patient and their legal representative are able to understand and sign the informed consent form, and are willing to comply with the follow-up and treatment plan specified in the study protocol.\n* Patients with nAMD who have already been determined to receive the faricimab (4 loading doses + PRN) treatment regimen based on clinical need, for post-treatment observation.\n* Only one eye will be selected as the study eye (if both eyes meet the criteria, the investigator will select the eye with worse visual acuity as the study eye).\n\nExclusion Criteria:\n\n* Patients with ocular or periocular infection.\n* Patients with active intraocular inflammation.\n* Known hypersensitivity to faricimab or any of its excipients.\n* Previous treatment with any other investigational therapy or any therapy that affects choroidal neovascularization (CNV) or macular neovascularization (MNV), or any therapy used for AMD.\n* Presence of any ocular or systemic disease other than nAMD that may affect visual acuity assessment.\n* Prior treatment in the study eye with anti-VEGF agents, corticosteroids, or laser therapy.\n* Structural damage to the fovea in the study eye that is likely to prevent BCVA improvement even after resolution of macular edema (e.g., retinal pigment epithelial atrophy, subretinal fibrosis or scar, significant macular ischemia, or organized hard exudates).\n* Presence of retinal pigment epithelial tear involving the macula in the study eye at screening.\n* Uncontrolled glaucoma in the study eye.\n* Refractive error in the study eye with spherical equivalent exceeding 6 diopters of myopia.\n* Any cataract surgery or steroid treatment for cataract surgery complications in the study eye within 6 months prior to screening.\n* Pregnant or breastfeeding women.\n* Patients considered unsuitable for study enrollment by the investigator for other reasons.\n* Inability to provide baseline clinical data (BCVA, visual contrast sensitivity, indocyanine green angiography (ICGA) images, optical coherence tomography angiography (OCTA) images, OCT images, color fundus photography (CFP) images) within 2 weeks (14 days) prior to the first faricimab treatment.","ALL","50 Years",{"count":18,"type":19},50,"ESTIMATED","OBSERVATIONAL","Evaluate the benefit of faricimab (4 loading doses + PRN) on best-corrected visual acuity in patients with nAMD. Evaluate the safety and anatomical improvement of faricimab (4 loading doses + PRN) in patients with nAMD.",[23],"Neovascular Age-related Macular Degeneration(nAMD)",[25,23,26],"Faricimab","Choroidal Vascularity Index (CVI)","NOT_YET_RECRUITING","2026-05-06",{"date":30,"type":31},"2026-05-12","ACTUAL",{"date":33,"type":19},"2026-06-01",{"date":35,"type":19},"2028-05-31",{"name":37,"class":38},"Sun Yat-sen University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":46,"targetDuration":48,"studyType":20,"phases":4,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":4},"100599742","therapeutic-prospects-of-faricimab-injection-for-patients-affected-by-neovascular-age-related-macular-degeneration-100599742","NCT07088445","Therapeutic Prospects of Faricimab Injection for Patients Affected by Neovascular Age-Related Macular Degeneration","Inclusion Criteria:\n\n* Diagnosis of wet age-related macular degeneration (nAMD) in individuals aged 50 years to 80 years.\n* Refractory nAMD: ≥ 6 injections of anti VEGF drugs within 12 months or ≥ 4 injections within 6 months, CFT ≥300 μm， In addition, there is retinal fluid.\n* BCVA is 24 to 73 letters (equivalent to Snellen vision of about 20\u002F40 to 20\u002F320) in the early treatment of diabetes retinopathy study (ETDRS) scoring scale.\n* The subjects can understand the purpose of the study and voluntarily sign a written informed consent.\n\nExclusion Criteria:\n\n* Accompanied by other eye diseases that may affect the structure or function of the macula (such as diabetes retinopathy, uveitis, etc.). There are obvious scars or fibrosis on the vitreous or retina.\n* There is uncontrolled hypertension, diabetes or other systemic diseases that may affect the treatment effect.\n* Having undergone eye surgery (such as retinal laser treatment or vitrectomy) and less than 3 months after surgery.\n* Allergic to farnesyl monoclonal antibody or its components.\n* Patients who are unable to complete follow-up or have poor compliance.\n* Researchers determine other factors that may affect the safety or data integrity of the experiment.",{"count":47,"type":19},35,"6 Months","Neovascular Age-Related Macular Degeneration (nAMD) is one of the main causes of irreversible vision loss in the elderly, characterized by neovascularization and vascular leakage in the macular area, ultimately leading to damage to retinal structure and visual impairment. At present, anti vascular endothelial growth factor (VEGF) therapy is the main approach for treating nAMD, including VEGF inhibitors such as Aflibercept and Conbercept. However, some patients show decreased treatment tolerance or efficacy after long-term use of these drugs . Faricimab, a bispecific antibody that targets both VEGF and angiopoietin-2 (Ang-2), is expected to provide a new treatment option for patients resistant to existing VEGF therapies due to its unique dual mechanism of action The aim of this study is to explore the treatment response rate and prognosis of farnesyl monoclonal antibody in patients with refractory nAMD, including visual improvement and imaging changes, in order to provide more scientific treatment decision-making basis for clinical practice. At the same time, to determine its efficacy and safety in actual clinical treatment, in order to provide more flexible and personalized treatment options for nAMD patients, reduce their treatment burden, improve treatment compliance and quality of life.",[23],"2025-07-20",{"date":53,"type":31},"2025-07-28",{"date":55,"type":19},"2025-09-01",{"date":57,"type":19},"2026-06-30",{"name":59,"class":38},"Hui Peng",{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":75,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":84,"locationsCount":87},"100518529","early-phase-1-crisprcas13-mediated-rna-targeting-therapy-for-the-treatment-of-neovascular-age-related-macular-degeneration-investigator-initiated-trial-sight-i-100518529","NCT06031727","CRISPR\u002Fcas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)","A Trial to Evaluate the Safety, Tolerability, and Efficacy of CRISPR-Cas13 RNA-editing Therapy Targeting Knockdown of Vascular Endothelial Growth Factor a (HG202) in the Treatment of Neovascular Age-related Macular Degeneration (nAMD)","Inclusion Criteria:\n\n* Males or females ≥ 50 and ≤ 80 years at the time of signing the ICF\n* Diagnosed of choroidal neovascularization (CNV) secondary to AMD in the study eye;\n* Best-corrected visual acuity (BCVA) ranged from 73 to 23 early treatment diabetic retinopathy study (ETDRS)letter score (corresponding to 20\u002F32 to 20\u002F320 of Snellen visual acuity) in the study eye;\n* BCVA in the non-study eye had an ETDRS letter score of 19(equivalent to Snellen visual acuity20\u002F400) and above;\n* Able to perform visual acuity and retinal function tests and able and willing to comply with study procedures for this clinical trial;\n\nRESPONSIVE SUBJECTS:\n\n* History of need for and responsive to anti-VEGF therapy in the study eye\n\nNON-RESPONSIVE SUBJECTS:\n\n* History of receiving anti-VEGF therapy but is resistant to treatment, which is defined as: a. complete or near-complete remission of subretinal fluid after the initial 3 doses of anti-VEGF agents and thenno improvement (less than 50um reduction) or deterioration of CRT by OCT\n\nExclusion Criteria:\n\n* Subretinal hemorrhage, scarring, or fibrosis of greater than 50% of the total lesion in the study eye;\n* Any condition in the Investigator's opinion that could limit visual improvement in the study eye;\n* Other ocular diseases that may affect central vision in the study eye (e.g., retinal vein occlusion, retinal detachment, macular hole, optic nerve disease, etc.);\n* Presence of CNV not due to nAMD in the study eye,\n* Uncontrolled glaucoma in the study eye;\n* Active intraocular inflammation or a history of uveitis in either eye;\n* History or presence of corneal dystrophy in the study eye;\n* Subjects with immunodeficiency diseases prone to opportunistic infections;\n* History of other intraocular surgery in the study eye within 3 months prior to baseline that in the Investigator's opinion could impact healing or study outcome interpretation;\n* Prior gene therapy or oligonucleotide therapy;\n* History of acute coronary syndrome, myocardial infarction, coronary revascularization, cerebrovascular accident, or transient ischemic attack within 6 months prior to the Screening Visit;\n* Other conditions judged by the investigator as inappropriate for the study.","80 Years",{"count":69,"type":19},12,"INTERVENTIONAL",[72],"EARLY_PHASE1","Age-related macular degeneration (AMD) is a progressive disease leading to severe and irreversible vision loss of which the neovascular AMD (nAMD) accounted for 90% blindness in AMD. nAMD is primarily driven by the perturbation of vascular endothelial growth factor (VEGF). VEGF overexpression leads to abnormal growth of choroidal neovascularization (CNV), which is a hallmark of AMD. Although anti-VEGF agents are effective in treating nAMD, long-term efficacy decreases over time due to the need for repeated injections impacting patient compliance with treatment regimen while patients still may lose vision during the 7th or 8th year of treatment. These frequent intravitreal injections can increase the risk of complications, including submacular hemorrhage, intraocular hypertension, inflammation, and retinal detachment. Furthermore, there are up to 46% of nAMD patients using anti-VEGF agents who have shown poor response or have developed tachyphylaxis with anti-VEGF therapies. HG202 is a CRISPR\u002FCas13 RNA-editing therapy packaging novel high-fidelity Cas13 technology using one single AAV vector to partially knock-down the expression of VEGFA and thus inhibit CNV formation in AMD patients who are either responsive or non-responsive to anti-VEGF agents. The long-term, stable delivery of HG202 following a one (1) time gene-editing therapy treatment for nAMD could potentially reduce the frequent injection treatment burden of currently available therapies AND treat nAMD patients who are non-responsive to anti-VEGF therapies and have no treatment.",[23],[76],"Macular Degeneration\u002FnAMD\u002FwAMD\u002FGene-editing\u002FCRISPR\u002FHG202","RECRUITING","2025-03-12",{"date":80,"type":31},"2025-03-17",{"date":82,"type":31},"2023-09-04",{"date":57,"type":19},{"name":85,"class":86},"HuidaGene Therapeutics Co., Ltd.","INDUSTRY",2]